Author: "Beitinjaneh, Amer" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Beitinjaneh, Amer"' showing total 663 results

Start Over Author "Beitinjaneh, Amer"

663 results on '"Beitinjaneh, Amer"'

1. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.

Author: Lin, Rick, Anderson, Anthony, Natori, Yoichiro, Raja, Mohammed, Morris, Michele, Jimenez, Antonio, Beitinjaneh, Amer, Wang, Trent, Goodman, Mark, Lekakis, Lazaros, Spiegel, Jay, Holtzman, Noa, Pereira, Denise, Benjamin, Cara, Natori, Akina, Komanduri, Krishna, and Camargo, Jose
Subjects: Humans, Cytomegalovirus Infections, Male, Virus Activation, Middle Aged, Female, Cytomegalovirus, Incidence, Immunotherapy, Adoptive, Adult, Receptors, Chimeric Antigen, Aged
Abstract: Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.
Published: 2024

2. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Author: Khera, Nandita, Ailawadhi, Sikander, Brazauskas, Ruta, Patel, Jinalben, Jacobs, Benjamin, Ustun, Celalettin, Ballen, Karen, Abid, Muhammad, Diaz Perez, Miguel, Al-Homsi, A, Hashem, Hasan, Hong, Sanghee, Munker, Reinhold, Schears, Raquel, Lazarus, Hillard, Ciurea, Stefan, Badawy, Sherif, Savani, Bipin, Wirk, Baldeep, LeMaistre, C, Bhatt, Neel, Beitinjaneh, Amer, Aljurf, Mahmoud, Sharma, Akshay, Cerny, Jan, Knight, Jennifer, Kelkar, Amar, Yared, Jean, Kindwall-Keller, Tamila, Winestone, Lena, Steinberg, Amir, Arnold, Staci, Seo, Sachiko, Preussler, Jaime, Hossain, Nasheed, Fingrut, Warren, Agrawal, Vaibhav, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William, Rangarajan, Hemalatha, Saber, Wael, and Hahn, Theresa
Subjects: Humans, Hematopoietic Stem Cell Transplantation, Male, Female, Adult, Middle Aged, Ethnic and Racial Minorities, Adolescent, Child, Aged, Young Adult, Child, Preschool
Abstract: There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P < .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.
Published: 2024

3. Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.

Author: Zinter, Matt, Brazauskas, Ruta, Strom, Joelle, Chen, Stella, Bo-Subait, Stephanie, Sharma, Akshay, Beitinjaneh, Amer, Dimitrova, Dimana, Guilcher, Greg, Preussler, Jaime, Myers, Kasiani, Bhatt, Neel, Ringden, Olle, Hematti, Peiman, Hayashi, Robert, Patel, Sagar, Rotz, Seth, Badawy, Sherif, Nishihori, Taiga, Buchbinder, David, Hamilton, Betty, Savani, Bipin, Schoemans, Hélène, Sorror, Mohamed, Duncan, Christine, Phelan, Rachel, Dvorak, Christopher, De Oliveira, Satiro, and Winestone, Lena
Subjects: Humans, Child, United States, Hematopoietic Stem Cell Transplantation, Transplant Recipients, Transplantation, Homologous, Graft vs Host Disease, Critical Care
Abstract: Allogeneic hematopoietic cell transplantation (HCT) can be complicated by life-threatening organ toxicity and infection necessitating intensive care. Epidemiologic data have been limited by single-center studies, poor database granularity, and a lack of long-term survivors. To identify contemporary trends in intensive care unit (ICU) use and long-term outcomes, we merged data from the Center for International Blood and Marrow Transplant Research and the Virtual Pediatric Systems databases. We identified 6995 pediatric patients with HCT aged ≤21 years who underwent first allogeneic HCT between 2008 and 2014 across 69 centers in the United States or Canada and followed patients until the year 2020. ICU admission was required for 1067 patients (8.3% by day +100, 12.8% by 1 year, and 15.3% by 5 years after HCT), and was linked to demographic background, pretransplant organ toxicity, allograft type and HLA-match, and the development of graft-versus-host disease or malignancy relapse. Survival to ICU discharge was 85.7%, but more than half of ICU survivors required ICU readmission, leading to 52.5% and 42.6% survival at 1- and 5-years post-ICU transfer, respectively. ICU survival was worse among patients with malignant disease, poor pretransplant organ function, and alloreactivity risk factors. Among 1-year HCT survivors, those who required ICU in the first year had 10% lower survival at 5 years and developed new dialysis-dependent renal failure at a greater rate (P
Published: 2024

4. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Author: Shadman, Mazyar, Ahn, Kwang W., Kaur, Manmeet, Lekakis, Lazaros, Beitinjaneh, Amer, Iqbal, Madiha, Ahmed, Nausheen, Hill, Brian, Hossain, Nasheed M., Riedell, Peter, Gopal, Ajay K., Grover, Natalie, Frigault, Matthew, Brammer, Jonathan, Ghosh, Nilanjan, Merryman, Reid, Lazaryan, Aleksandr, Ram, Ron, Hertzberg, Mark, Savani, Bipin, Awan, Farrukh, Khimani, Farhad, Ahmed, Sairah, Kenkre, Vaishalee P., Ulrickson, Matthew, Shah, Nirav, Kharfan-Dabaja, Mohamed A., Herrera, Alex, Sauter, Craig, and Hamadani, Mehdi
Published: 2024
Full Text: View/download PDF

5. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.

Author: Wang, Yucai, Jain, Preetesh, Locke, Frederick, Maurer, Matthew, Frank, Matthew, Munoz, Javier, Dahiya, Saurabh, Beitinjaneh, Amer, Jacobs, Miriam, Mcguirk, Joseph, Vose, Julie, Goy, Andre, Hill, Brian, Dorritie, Kathleen, Oluwole, Olalekan, Deol, Abhinav, Paludo, Jonas, Shah, Bijal, Wang, Trent, Banerjee, Rahul, Miklos, David, Rapoport, Aaron, Lekakis, Lazaros, Ghobadi, Armin, Neelapu, Sattva, Lin, Yi, Wang, Michael, Jain, Michael, and Andreadis, Charalambos
Subjects: Adult, Humans, Receptors, Chimeric Antigen, Lymphoma, Mantle-Cell, Bendamustine Hydrochloride, Neoplasm Recurrence, Local, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Antigens, CD19
Abstract: PURPOSE: Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates of 91% and 68%, respectively. We report clinical outcomes with brexu-cel in the standard-of-care setting for the approved indication. PATIENTS AND METHODS: Patients who underwent leukapheresis between August 1, 2020 and December 31, 2021, at 16 US institutions, with an intent to manufacture commercial brexu-cel for relapsed/refractory MCL, were included. Patient data were collected for analyses of responses, outcomes, and toxicities as per standard guidelines. RESULTS: Of 189 patients who underwent leukapheresis, 168 (89%) received brexu-cel infusion. Of leukapheresed patients, 79% would not have met ZUMA-2 eligibility criteria. Best overall and complete response rates were 90% and 82%, respectively. At a median follow-up of 14.3 months after infusion, the estimates for 6- and 12-month progression-free survival (PFS) were 69% (95% CI, 61 to 75) and 59% (95% CI, 51 to 66), respectively. The nonrelapse mortality was 9.1% at 1 year, primarily because of infections. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 8% and 32%, respectively. In univariable analysis, high-risk simplified MCL international prognostic index, high Ki-67, TP53 aberration, complex karyotype, and blastoid/pleomorphic variant were associated with shorter PFS after brexu-cel infusion. Patients with recent bendamustine exposure (within 24 months before leukapheresis) had shorter PFS and overall survival after leukapheresis in intention-to-treat univariable analysis. CONCLUSION: In the standard-of-care setting, the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
Published: 2023

6. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.

Author: Saliba, Rima, Alousi, Amin, Pidala, Joseph, Arora, Mukta, Spellman, Stephen, Hemmer, Michael, Wang, Tao, Abboud, Camille, Ahmed, Sairah, Antin, Joseph, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Choe, Hannah, Hanna, Rabi, Hematti, Peiman, Kamble, Rammurti, Kitko, Carrie, Laughlin, Mary, Lekakis, Lazaros, MacMillan, Margaret, Martino, Rodrigo, Mehta, Parinda, Nishihori, Taiga, Patel, Sagar, Perales, Miguel-Angel, Rangarajan, Hemalatha, Ringdén, Olov, Rosenthal, Joseph, Savani, Bipin, Schultz, Kirk, Seo, Sachiko, Teshima, Takanori, van der Poel, Marjolein, Verdonck, Leo, Weisdorf, Daniel, Wirk, Baldeep, Yared, Jean, Schriber, Jeffrey, Champlin, Richard, and Ciurea, Stefan
Subjects: Graft-versus-host disease, Non-relapse mortality, Post-transplantation cyclophosphamide, Prophylaxis, Antilymphocyte Serum, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Retrospective Studies
Abstract: Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes in patients with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor transplantation with conventional prophylaxis (MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD (aGvHD) including 264 and 1163 recipients of Haplo and MUD transplants; and patients with any chronic GvHD (cGvHD) including 206 and 1018 recipients of Haplo and MUD transplants, respectively. In comparison with MUD/conventional transplantation ± antithymocyte globulin (ATG), grade 3-4 aGvHD (28% versus 39%, P = .001), stage 3-4 lower gastrointestinal (GI) tract aGvHD (14% versus 21%, P = .01), and chronic GI GvHD (21% versus 31%, P = .006) were less common after Haplo/PTCy transplantation. In patients with grade 2-4 aGvHD, cGvHD rate after Haplo/PTCY was also lower (hazard ratio [HR] = .4, P < .001) in comparison with MUD/conventional transplantation without ATG in the nonmyeloablative conditioning setting. Irrespective of the use of ATG, non-relapse mortality rate was lower (HR = .6, P = .01) after Haplo/PTCy transplantation, except for transplants that were from a female donor into a male recipient. In patients with cGvHD, irrespective of ATG use, Haplo/PTCy transplantation had lower non-relapse mortality rates (HR = .6, P = .04). Mortality rate was higher (HR = 1.6, P = .03) during, but not after (HR = .9, P = .6) the first 6 months after cGvHD diagnosis. Our results suggest that PTCy-based GvHD prophylaxis mitigates the development of GI GvHD and may translate into lower GvHD-related non-relapse mortality rate.
Published: 2022

7. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study

Author: Kahn, Justine, Brazauskas, Ruta, Bo-Subait, Stephanie, Buchbinder, David, Hamilton, Betty K, Schoemans, Hélène, Abraham, Allistair A, Agrawal, Vaibhav, Auletta, Jeffery J, Badawy, Sherif M, Beitinjaneh, Amer, Bhatt, Neel S, Broglie, Larisa, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, Cesar O, Gale, Robert Peter, Ganguly, Siddhartha, Hayashi, Robert J, Hematti, Peiman, Hildebrandt, Gerhard C, Inamoto, Yoshihiro, Kamble, Rammurti T, Koo, Jane, Lazarus, Hillard M, Mayo, Samantha J, Mehta, Parinda A, Myers, Kasiani C, Nishihori, Taiga, Prestidge, Tim, Rotz, Seth J, Savani, Bipin N, Schears, Raquel M, Sharma, Akshay, Stenger, Elizabeth, Ustun, Celalettin, Williams, Kirsten M, Vrooman, Lynda M, Satwani, Prakash, and Phelan, Rachel
Published: 2024
Full Text: View/download PDF

8. Racial, ethnic, and socioeconomic diversity and outcomes of patients with graft-versus-host disease: a CIBMTR analysis

Author: Farhadfar, Nosha, Rashid, Nahid, Chen, Karen, DeVos, Jakob, Wang, Tao, Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Hamilton, Betty K., Hematti, Peiman, Gadalla, Shahinaz M., Solomon, Scott R., El Jurdi, Najla, Lee, Catherine J., MacMillan, Margaret L., Rangarajan, Hemalatha G., Schoemans, Hélène, Sharma, Akshay, Spellman, Stephen R., Wingard, John R., and Lee, Stephanie J.
Published: 2024
Full Text: View/download PDF

9. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant

Author: Jimenez, Antonio Jimenez, Komanduri, Krishna, Brown, Samantha, Wang, Trent, Pereira, Denise, Goodman, Mark, Beitinjaneh, Amer, Lekakis, Lazaros, Chinapen, Stephanie, Devlin, Sean, Ponce, Doris, Sauter, Craig, Perales, Miguel-Angel, and Shaffer, Brian C
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Clinical Research, Clinical Trials and Supportive Activities, Transplantation, Cancer, Prevention, Hematology, Good Health and Well Being, Antilymphocyte Serum, Cyclophosphamide, Graft vs Host Disease, Humans, Methotrexate, Prospective Studies, Tacrolimus, Unrelated Donors, Cardiovascular medicine and haematology
Abstract: A common method to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT) from an HLA-mismatched unrelated donor (MMUD) is tacrolimus, methotrexate, and antithymocyte globulin (ATG). The use of posttransplant cyclophosphamide (PTCy) showed promise in a prospective trial for MMUD HCT. We compared 1-year graft-versus-host disease-free, relapse-free survival (GRFS) in 128 recipients of prophylaxis based on tacrolimus/methotrexate/ATG (ATG group, n = 46) vs PTCy, mycophenolate mofetil, and tacrolimus or sirolimus (PTCy group, n = 82) after MMUD HCT. Patients receiving HCT from a MMUD mismatched at ≥1 locus among HLA-A, HLA-B, HLA-C, and HLA-DRB1 were included. The 2 groups were well matched for HCT indication, high-risk disease, and HCT comorbidity index, whereas more patients on PTCy received bone marrow (50% vs 26%; P = .01) and >1 locus HLA-mismatched (30.5% vs 2.2%; P = .001) grafts. The 1-year GRFS was 16% (95% confidence interval (CI): 8%-31%) vs 54% (95% CI: 44%-66%; P < .001) in the ATG and PTCy groups, respectively. The multivariable adjusted hazard ratio for GRFS was 0.34 (95% CI: 0.21-0.55; P < .001) with the use of PTCy. The 1-year overall survival in the ATG group was 45% (95% CI: 32%-62%) vs 75% (95% CI: 66%-85%) in the PTCy group (P < .001). Relapse incidence was similar. One-year nonrelapse mortality was greater after ATG-based prophylaxis: 38% (95% CI: 23%-52%) vs 16% (95 CI: 9%-25%), P < .001. In summary, PTCy-based prophylaxis resulted in superior GRFS and overall survival in recipients of MMUD.
Published: 2022

10. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author: Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas
Published: 2024
Full Text: View/download PDF

11. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Author: Mahadeo, Kris Michael, Baiocchi, Robert, Beitinjaneh, Amer, Chaganti, Sridhar, Choquet, Sylvain, Dierickx, Daan, Dinavahi, Rajani, Duan, Xinyuan, Gamelin, Laurence, Ghobadi, Armin, Guzman-Becerra, Norma, Joshi, Manher, Mehta, Aditi, Navarro, Willis H, Nikiforow, Sarah, O'Reilly, Richard J, Reshef, Ran, Ruiz, Fiona, Spindler, Tassja, and Prockop, Susan
Published: 2024
Full Text: View/download PDF

12. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Author: Singh, Anurag, Dandoy, Christopher E, Chen, Min, Kim, Soyoung, Mulroney, Carolyn M, Kharfan-Dabaja, Mohamed A, Ganguly, Siddhartha, Maziarz, Richard T, Kanakry, Christopher G, Kanakry, Jennifer A, Patel, Sagar S, Hill, Joshua A, De Oliveir, Satiro, Taplitz, Randy, Hematti, Peiman, Lazarus, Hillard M, Abid, Muhammad Bilal, Goldsmith, Scott R, Romee, Rizwan, Komanduri, Krishna V, Badawy, Sherif M, Friend, Brian D, Beitinjaneh, Amer, Politikos, Ioannis, Perales, Miguel-Angel, and Riches, Marcie
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Cancer, Clinical Research, Stem Cell Research - Nonembryonic - Human, Hematology, Stem Cell Research, Transplantation, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Cyclophosphamide, Cytomegalovirus Infections, Herpesviridae, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Prospective Studies, Non-CMV herpesvirus, Post-transplantation, cyclophosphamide, Haploidentical, Epstein-Barr virus, HHV-6, Post-transplantation cyclophosphamide, Clinical Sciences, Cardiovascular medicine and haematology
Abstract: The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings.
Published: 2022

13. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author: Jimenez Jimenez, Antonio M, De Lima, Marcos, Komanduri, Krishna V, Wang, Trent P, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R, Hildebrandt, Gerhard C, Hogan, William J, Kanakry, Christopher G, Kansagra, Ankit, Kharfan-Dabaja, Mohamed A, Khera, Nandita, Krem, Maxwell M, Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S, Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F, Wirk, Baldeep, Yared, Jean A, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S, Saber, Wael, and Weisdorf, Daniel
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Genetics, Transplantation, Pediatric Research Initiative, Childhood Leukemia, Stem Cell Research, Cancer, Clinical Research, Pediatric Cancer, Rare Diseases, Pediatric, Stem Cell Research - Nonembryonic - Human, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Retrospective Studies, Risk Assessment, Transplantation Conditioning, Transplantation, Homologous, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract: Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p
Published: 2021

14. Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy

Author: Camargo, Jose F, Mendoza, Maria A, Lin, Rick, Moroz, Ilona V, Anderson, Anthony D, Morris, Michelle I, Natori, Yoichiro, Natori, Akina, Raja, Mohammed, Lekakis, Lazaros, Beitinjaneh, Amer, Jimenez, Antonio, Goodman, Mark, Wang, Trent, Komanduri, Krishna V, and Pereira, Denise
Subjects: Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Clinical Research, Good Health and Well Being, COVID-19, COVID-19 Testing, Cell- and Tissue-Based Therapy, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Retrospective Studies, SARS-CoV-2, hematopoietic cell transplantation, Surgery, Clinical sciences
Abstract: BackgroundOne year into the pandemic, published data on hematopoietic cell transplantation (HCT) recipients with coronavirus disease 2019 (COVID-19) remain limited.MethodsSingle-center retrospective cohort study of adult HCT recipients with polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.ResultsTwenty-eight consecutive transplantation and cellular therapy patients (autologous, n = 12; allogeneic, n = 15; chimeric antigen receptor T-cell therapy [CAR-T], n = 1) with COVID-19 were identified. The median age was 57 years. The median time from HCT to COVID-19 diagnosis was 656 days (interquartile range [IQR], 33-1274). Patients were followed for a median of 59 days (IQR, 40-88). Among assessable patients (n = 19), 10 (53%) had documented virological clearance; median time to clearance was 34 days (range, 21-56). Out of 28, 12 (43%), 6 (21%), and 10 (36%) patients had mild, moderate, and severe/critical disease, respectively. Overall mortality was 25%, nearly identical for autologous and allogeneic HCT, and exclusively seen in hospitalized patients, older than 50 years of age with severe COVID-19. None of the patients with mild (n = 12) or moderate (n = 6) COVID-19 died whereas 7/10 patients (70%) with severe/critical COVID-19 died (P = .0001). Patients diagnosed with COVID-19 within 12 months of HCT exhibited higher mortality (57% vs 14%; P = .04). All-cause 30-day mortality (n = 4) was 14%. A higher proportion of patients who died within 30 days of COVID-19 diagnosis (3/4) were receiving ≥2 immunosuppressants, compared with patients who survived beyond 30 days after COVID-19 diagnosis (2/24; 75% vs. 8%; P = .01).ConclusionsMortality in COVID-19 HCT patients is higher than that of the age-comparable general population and largely dependent on age, disease severity, timing from HCT, and intensity of immunosuppression.
Published: 2021

15. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States

Author: Bhatt, Neel S, Brazauskas, Ruta, Salit, Rachel B, Syrjala, Karen, Bo-Subait, Stephanie, Tecca, Heather, Badawy, Sherif M, Baker, K Scott, Beitinjaneh, Amer, Bejanyan, Nelli, Byrne, Michael, Dias, Ajoy, Farhadfar, Nosha, Freytes, César O, Ganguly, Siddhartha, Hashmi, Shahrukh, Hayashi, Robert J, Hong, Sanghee, Inamoto, Yoshihiro, Jamani, Kareem, Kasow, Kimberly A, Khera, Nandita, Krem, Maxwell M, Lazarus, Hillard M, Lee, Catherine J, Lee, Stephanie, Majhail, Navneet S, Malone, Adriana K, Marks, David I, Mau, Lih-Wen, Mayo, Samantha J, Muffly, Lori S, Nathan, Sunita, Nishihori, Taiga, Page, Kristin M, Preussler, Jaime, Rangarajan, Hemalatha G, Rotz, Seth J, Salooja, Nina, Savani, Bipin N, Schears, Raquel, Schechter-Finkelstein, Tal, Schiller, Gary, Shah, Ami J, Sharma, Akshay, Wang, Trent, Wirk, Baldeep, Battiwalla, Minoo, Schoemans, Hélène, Hamilton, Betty, Buchbinder, David, Phelan, Rachel, and Shaw, Bronwen
Subjects: Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Transplantation, Clinical Research, Rehabilitation, Behavioral and Social Science, Quality Education, Female, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Return to Work, Survivors, Transplantation, Homologous, United States, Young Adult, Hematopoietic cell transplantation, Return to work, Quality of life, Young adult, Immunology, Cardiovascular medicine and haematology
Abstract: Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population remain understudied, however. We conducted this study to assess the post-HCT work status of survivors of allogeneic HCT who underwent HCT as YAs and to analyze the patient-, disease-, and HCT-related factors associated with their work status at 1 year post-HCT. Using Center for International Blood and Marrow Transplant Research data, we evaluated the post-HCT work status (full-time, part-time work, unemployed, or medical disability) of 1365 YA HCT survivors who underwent HCT between 2008 and 2015. Percentages of work status categories were reported at 4 time points: 6 months, 1 year, 2 years, and 3 years post-HCT. Percentages of post-HCT work status categories at the 1-year time point were also described in relation to survivors' pre-HCT work status categories. Factors associated with 1-year post-HCT work status (full-time or part-time work) were examined using logistic regression. From 6 months to 3 years post-HCT, the percentage of survivors working full-time increased from 18.3% to 50.7% and the percentage working part-time increased from 6.9% to 10.5%. Of patients in full-time work pre-HCT, 50% were unemployed or on medical disability at 1 year post-HCT. Female sex (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.40 to 0.77), HCT Comorbidity Index score ≥3 (OR, 0.57; 95% CI, 0.39 to 0.82), pre-HCT unemployment (OR, 0.37; 95% CI, 0.24 to 0.56), medical disability (OR, 0.44; 95% CI, 0.28 to 0.70), development of grade III-IV acute graft-versus-host disease (OR, 0.52; 95% CI, 0.34 to 0.80), and relapse within 1 year post-HCT (OR, 0.34; 95% CI, 0.21 to 0.56) were associated with a lower likelihood of employment at 1 year post-HCT. Compared with myeloablative conditioning (MAC) with total body irradiation (TBI), MAC without TBI (OR, 1.71; 95% CI, 1.16 to 2.53) was associated with a greater likelihood of employment at 1 year post-HCT. Graduate school-level education (OR, 2.47; 95% CI, 1.49 to 4.10) was also associated with a greater likelihood of employment at 1 year post-HCT. Although the work status among YA HCT survivors continued to improve over time, a substantial subset became or remained unemployed or on medical disability. These findings underscore the need for effective interventions to support return to work in this population.
Published: 2021

16. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author: Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract: The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.
Published: 2021

17. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Author: Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.
Published: 2023
Full Text: View/download PDF

18. Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma

Author: Benjamin, Cara L., Desai, Shreena, Pereira, Denise, Beitinjaneh, Amer, Jimenez, Antonio, Goodman, Mark, Lekakis, Lazaros, Spiegel, Jay, Komanduri, Krishna V., and Wang, Trent P.
Published: 2023
Full Text: View/download PDF

19. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author: Hong, Sanghee, Brazauskas, Ruta, Hebert, Kyle M, Ganguly, Siddhartha, Abdel‐Azim, Hisham, Diaz, Miguel Angel, Beattie, Sara, Ciurea, Stefan O, Szwajcer, David, Badawy, Sherif M, Gratwohl, Alois A, LeMaistre, Charles, Aljurf, Mahmoud DSM, Olsson, Richard F, Bhatt, Neel S, Farhadfar, Nosha, Yared, Jean A, Yoshimi, Ayami, Seo, Sachiko, Gergis, Usama, Beitinjaneh, Amer M, Sharma, Akshay, Lazarus, Hillard, Law, Jason, Ulrickson, Matthew, Hashem, Hasan, Schoemans, Hélène, Cerny, Jan, Rizzieri, David, Savani, Bipin N, Kamble, Rammurti T, Shaw, Bronwen E, Khera, Nandita, Wood, William A, Hashmi, Shahrukh, Hahn, Theresa, Lee, Stephanie J, Rizzo, J Douglas, Majhail, Navneet S, and Saber, Wael
Subjects: Hematology, Cancer, Clinical Research, Prevention, Transplantation, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Community Health Planning, Female, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Public Health, Risk Factors, Transplantation, Homologous, Treatment Outcome, United States, Young Adult, allogeneic transplant, community health, hematopoietic cell transplantation, survival, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract: BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
Published: 2021

20. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author: Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael
Published: 2023
Full Text: View/download PDF

21. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Author: Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret, Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet, Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery, Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard, Lad, Deepesh, Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti, Kharfan-Dabaja, Mohamed, Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant, Nishihori, Taiga, OBrien, Tracey, Olsson, Richard, Patel, Sagar, Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John, William, Basem, Wirk, Baldeep, Yared, Jean, Spellman, Steve, Arora, Mukta, and Hamilton, Betty
Subjects: Adult, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Risk Factors, Transplantation Conditioning
Abstract: Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus
Published: 2020

22. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author: Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract: Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.
Published: 2020

23. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?

Author: Beitinjaneh, Amer, Kaufman, Adrienne, Wang, Yucai, Jain, Preetesh, Srour, Samer A, and Wang, Michael
Published: 2022
Full Text: View/download PDF

24. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

Author: Ballen, Karen, Wang, Tao, He, Naya, Knight, Jennifer M., Hong, Sanghee, Frangoul, Haydar, Verdonck, Leo F., Steinberg, Amir, Diaz, Miguel A., LeMaistre, C. Fred, Badawy, Sherif M., Pu, Jeffrey J., Hashem, Hasan, Savani, Bipin, Sharma, Akshay, Lazarus, Hillard M., Abid, Muhammad Bilal, Tay, Jason, Rangarajan, Hemalatha G., Kindwall-Keller, Tamila, Freytes, Cesar O., Beitinjaneh, Amer, Winestone, Lena E., Gergis, Usama, Farhadfar, Nosha, Bhatt, Neel S., Schears, Raquel M., Gómez-Almaguer, David, Aljurf, Mahmoud, Agrawal, Vaibhav, Kuwatsuka, Yachiyo, Seo, Sachiko, Marks, David I., Lehmann, Leslie, Wood, William A., Hashmi, Shahrukh, and Saber, Wael
Published: 2024
Full Text: View/download PDF

25. S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY

Author: Claire Roddie, Karamjeet Sandhu, Eleni Tholouli, Paul Shaughnessy, Pere Barba Suñol, Manuel Nuno Direito de Morais Guerreiro, Mehrdad Abedi, Michael Bishop, Jean Yared, Armin Ghobadi, Deborah Yallop, Aaron Logan, Beitinjaneh Amer, Jeremy Pantin, Martha L Arellano, Sridhar Chaganti, Ram Malladi, Tobias Menne, Virginia Escamilla, Katharine Hodby, Krishna Gundabolu, Luke Mountjoy, Kristen Odwyer, Sameem Abedin, Hassan Alkhateeb, Bijal Shah, Silvia Basilico, Deborah Cluxton, Joanna Dawes, Pierre Lao-Sirieix, Meera Raymond, Justin Shang, Yanqing Hu, Gianfranco Pittari, Kapil Saxena, Wolfram Brugger, Y Zhang, Martin Pule, Daniel Park, Daniel De Angelo, and Elias Jabbour
Subjects: Diseases of the blood and blood-forming organs, RC633-647.5
Published: 2023
Full Text: View/download PDF

26. P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

Author: Mahadeo Kris Michael, Baiocchi Robert, Beitinjaneh Amer, Chaganti Sridhar, Sylvain Choquet, Daan Dierickx, Dinavahi Rajani, Laurence Gamelin, Armin Ghobadi, Guzman-Becerra Norma, Joshi Manher, Mehta Aditi, Nikiforow Sarah, Reshef Ran, Ye Wei, and Prockop Susan
Subjects: Diseases of the blood and blood-forming organs, RC633-647.5
Published: 2023
Full Text: View/download PDF

27. Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study

Author: Papanicolaou, Genovefa A, Ustun, Celalettin, Young, Jo-Anne H, Chen, Min, Kim, Soyoung, Ahn, Kwang Woo, Komanduri, Krishna, Lindemans, Caroline, Auletta, Jeffery J, Riches, Marcie L, Abdel-Azim, Hisham, Ahmed, Ibrahim A, Aljurf, Mahmoud, Antin, Joseph, Ballen, Karen Kuhn, Beitinjaneh, Amer, Brown, Valerie I, Cerny, Jan, Champlin, Richard, Chao, Nelson, Chhabra, Saurabh, Dahi, Parastoo B, Daly, Andrew, Dandoy, Christopher, Dvorak, Christopher C, Forman, Stephen, Ganguly, Siddhartha, Hashmi, Shahrukh K, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard, Ljungman, Per, Malone, Adriana K, Murthy, Nishihori, Taiga, Page, Kristin, Pingali, Ravi, Reddy, Vijay, Saad, Ayman, Savani, Bipin N, Seftel, Matthew, Szer, Jeffrey, Vij, Ravi, Weisdorf, Daniel, William, Basem M, Williams, Kirsten, Wirk, Baldeep, and Yared, Jean
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Cancer, Vaccine Related, Transplantation, Rare Diseases, Hematology, Emerging Infectious Diseases, Clinical Research, Good Health and Well Being, Adolescent, Adult, Aged, Anti-Bacterial Agents, Bacteremia, Child, Child, Preschool, Gram-Positive Bacterial Infections, Hematopoietic Stem Cell Transplantation, Humans, Infant, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Transplantation Conditioning, Vancomycin, Vancomycin-Resistant Enterococci, Young Adult, vancomycin-resistant Enterococcus, bacteremia, hematopoietic stem cell transplantation, mortality, CIBMTR® Infection and Immune Reconstitution Working Committee, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract: BackgroundWe examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the Center for International Blood and Marrow Transplant Research database.MethodsAdult and pediatric patients (N = 7128) who underwent first HCT for acute leukemia or myelodysplastic syndrome from 2008 through 2012 were analyzed as 3 groups-VRE BSI, non-VRE BSI, without BSI-according to BSI status at 100 days (D100) after allogeneic HCT. Multivariable models examined the effect of VRE BSI for overall survival (OS) and nonrelapse mortality (NRM) at 1 year.ResultsOf 7128 patients, 258 (3.2%) had VRE BSI, 2398 (33.6%) had non-VRE BSI, and 4472 (63%) had no BSI. The median time to VRE BSI and non-VRE BSI were D11 and D15, respectively. Compared with non-VRE BSI patients, VRE BSI patients were older, had advanced-stage acute leukemia, and received umbilical cord blood (UCB) allografts. In multivariable models, VRE BSI was associated with lower OS (relative risk [RR], 2.9;(99% confidence interval [CI], 2.2-3.7) and increased NRM (RR, 4.7; 99% CI, 3.6-6.2) (P < .0001) for both. Other predictors for worse OS and increased NRM were non-VRE BSI, older age, advanced disease stage, UCB allograft, - mismatch, comorbidity index ≥3, and cytomegalovirus seropositivity (P < .001 for all variables).ConclusionsVRE BSI is associated with lowest OS and highest NRM compared with patients without BSI or non-VRE BSI. Novel interventions that address the pathophysiology of VRE BSI have the potential of improving survival after HCT.
Published: 2019

28. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Author: Bejanyan, Nelli, Kim, Soyoung, Hebert, Kyle M, Kekre, Natasha, Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Badawy, Sherif M, Beitinjaneh, Amer, Boelens, Jaap Jan, Diaz, Miguel Angel, Dvorak, Christopher C, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Ganguly, Siddhartha, Gennery, Andrew R, George, Biju, Gergis, Usama, Gómez-Almaguer, David, Vicent, Marta Gonzalez, Hashem, Hasan, Kamble, Rammurti T, Kasow, Kimberly A, Lazarus, Hillard M, Mathews, Vikram, Orchard, Paul J, Pulsipher, Michael, Ringden, Olle, Schultz, Kirk, Teira, Pierre, Woolfrey, Ann E, Saldaña, Blachy Dávila, Savani, Bipin, Winiarski, Jacek, Yared, Jean, Weisdorf, Daniel J, Antin, Joseph H, and Eapen, Mary
Subjects: Transplantation, Regenerative Medicine, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Prevention, Hematology, Rare Diseases, Good Health and Well Being, Adolescent, Adult, Anemia, Aplastic, Bone Marrow Transplantation, Clinical Decision-Making, Disease Management, Graft vs Host Disease, HLA Antigens, Histocompatibility Testing, Humans, Prognosis, Severity of Illness Index, Siblings, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Young Adult
Abstract: Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used for BMT. We evaluated transplant conditioning regimens for BMT in SAA after HLA-matched sibling and unrelated donor BMT. For recipients of HLA-matched sibling donor transplantation (n = 955), fludarabine (Flu)/cyclophosphamide (Cy)/antithymocyte globulin (ATG) or Cy/ATG led to the best survival. The 5-year probabilities of survival with Flu/Cy/ATG, Cy/ATG, Cy ± Flu, and busulfan/Cy were 91%, 91%, 80%, and 84%, respectively (P = .001). For recipients of 8/8 and 7/8 HLA allele-matched unrelated donor transplantation (n = 409), there were no differences in survival between regimens. The 5-year probabilities of survival with Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG/total body irradiation 200 cGy, Flu/Cy/ATG, and Cy/ATG were 77%, 80%, 75%, and 72%, respectively (P = .61). Rabbit-derived ATG compared with equine-derived ATG was associated with a lower risk of grade II to IV acute graft-versus-host disease (GVHD) (hazard ratio [HR], 0.39; P < .001) but not chronic GVHD. Independent of conditioning regimen, survival was lower in patients aged >30 years after HLA-matched sibling (HR, 2.74; P < .001) or unrelated donor (HR, 1.98; P = .001) transplantation. These data support Flu/Cy/ATG and Cy/ATG as optimal regimens for HLA-matched sibling BMT. Although survival after an unrelated donor BMT did not differ between regimens, use of rabbit-derived ATG may be preferred because of lower risks of acute GVHD.
Published: 2019

29. Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1

Author: Ustun, Celalettin, Kim, Soyoung, Chen, Min, Beitinjaneh, Amer M, Brown, Valerie I, Dahi, Parastoo B, Daly, Andrew, Diaz, Miguel Angel, Freytes, Cesar O, Ganguly, Siddhartha, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Lazarus, Hillard M, Nishihori, Taiga, Olsson, Richard F, Page, Kristin M, Papanicolaou, Genovefa, Saad, Ayman, Seo, Sachiko, William, Basem M, Wingard, John R, Wirk, Baldeep, Yared, Jean A, Perales, Miguel-Angel, Auletta, Jeffery J, Komanduri, Krishna V, Lindemans, Caroline A, and Riches, Marcie L
Subjects: Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research - Nonembryonic - Human, Hematology, Infectious Diseases, Transplantation, Stem Cell Research, Clinical Research, Infection, Good Health and Well Being, Adult, Bacterial Infections, Hematopoietic Stem Cell Transplantation, Humans, Infections, Leukemia, Myeloid, Acute, Myeloablative Agonists, Remission Induction, Time Factors, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome, Cardiovascular medicine and haematology
Abstract: Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT-comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range,
Published: 2019

30. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation

Author: Ustun, Celalettin, Young, Jo-Anne H, Papanicolaou, Genovefa A, Kim, Soyoung, Ahn, Kwang Woo, Chen, Min, Abdel-Azim, Hisham, Aljurf, Mahmoud, Beitinjaneh, Amer, Brown, Valerie, Cerny, Jan, Chhabra, Saurabh, Kharfan-Dabaja, Mohamed A, Dahi, Parastoo B, Daly, Andrew, Dandoy, Christopher E, Dvorak, Christopher C, Freytes, Cesar O, Hashmi, Shahrukh, Lazarus, Hillard, Ljungman, Per, Nishihori, Taiga, Page, Kristin, Pingali, Sai RK, Saad, Ayman, Savani, Bipin N, Weisdorf, Daniel, Williams, Kirsten, Wirk, Baldeep, Auletta, Jeffery J, Lindemans, Caroline A, Komanduri, Krishna, and Riches, Marcie
Subjects: Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Hematology, Good Health and Well Being, Adolescent, Adult, Bacteremia, Child, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Mortality, Risk Factors, Transplantation Conditioning, Transplantation, Homologous, Young Adult, Oncology and Carcinogenesis, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract: We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had ≥1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n = 1492), 31% (n = 824), and 13% (n = 340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61-48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63-2.04 for BSI-VEP, RR 2.46, 95% CI 2.05-2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87-2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26-1.47 for BSI-VEP; RR 1.83, 95% CI 1.58-2.12 for BSI-LEP: RR 1.66, 95% CI 1.43-1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.
Published: 2019

31. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Author: Rashidi, Armin, Hamadani, Mehdi, Zhang, Mei-Jie, Wang, Hai-Lin, Abdel-Azim, Hisham, Aljurf, Mahmoud, Assal, Amer, Bajel, Ashish, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Bolaños-Meade, Javier, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Ciurea, Stefan, Copelan, Edward, Cutler, Corey, Daly, Andrew, Diaz, Miguel-Angel, Farhadfar, Nosha, Gale, Robert, Ganguly, Siddhartha, Grunwald, Michael, Hahn, Theresa, Hashmi, Shahrukh, Hildebrandt, Gerhard, Holland, H, Hossain, Nasheed, Kanakry, Christopher, Kharfan-Dabaja, Mohamed, Khera, Nandita, Koc, Yener, Lazarus, Hillard, Lee, Jong-Wook, Maertens, Johan, Martino, Rodrigo, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Palmisiano, Neil, Patel, Sagar, Pidala, Joseph, Olin, Rebecca, Olsson, Richard, Oran, Betul, Ringden, Olov, Rizzieri, David, Rowe, Jacob, Savoie, Mary, Schultz, Kirk, Seo, Sachiko, Shaffer, Brian, Singh, Anurag, Solh, Melhem, Stockerl-Goldstein, Keith, Verdonck, Leo, Wagner, John, Waller, Edmund, De Lima, Marcos, Sandmaier, Brenda, Litzow, Mark, Weisdorf, Dan, Romee, Rizwan, and Saber, Wael
Subjects: Adolescent, Adult, Aged, Blood Donors, Bone Marrow Transplantation, Calcineurin Inhibitors, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract: HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.
Published: 2019

32. Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation

Author: Patel, Sagar S., Ahn, Kwang Woo, Khanal, Manoj, Bupp, Caitrin, Allbee-Johnson, Mariam, Majhail, Navneet S., Hamilton, Betty K., Rotz, Seth J., Hashem, Hasan, Beitinjaneh, Amer, Lazarus, Hillard M., Krem, Maxwell M., Prestidge, Tim, Bhatt, Neel S., Sharma, Akshay, Gadalla, Shahinaz M., Murthy, Hemant S., Broglie, Larisa, Nishihori, Taiga, Freytes, César O., Hildebrandt, Gerhard C., Gergis, Usama, Seo, Sachiko, Wirk, Baldeep, Pasquini, Marcelo C., Savani, Bipin N., Sorror, Mohamed L., Stadtmauer, Edward A., and Chhabra, Saurabh
Published: 2022
Full Text: View/download PDF

33. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Author: Shadman, Mazyar, Pasquini, Marcelo, Ahn, Kwang Woo, Chen, Yue, Turtle, Cameron J., Hematti, Peiman, Cohen, Jonathon B., Khimani, Farhad, Ganguly, Siddhartha, Merryman, Reid W., Yared, Jean A., Locke, Frederick L., Ahmed, Nausheen, Munshi, Pashna N., Beitinjaneh, Amer, Reagan, Patrick M., Herrera, Alex F., Sauter, Craig S., Kharfan-Dabaja, Mohamed A., and Hamadani, Mehdi
Published: 2022
Full Text: View/download PDF

34. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Author: Bhatt, Vijaya Raj, Wang, Tao, Chen, Karen, Kitko, Carrie L., MacMillan, Margaret L., Pidala, Joseph A., Al Malki, Monzr M., Badawy, Sherif M., Beitinjaneh, Amer, Ganguly, Siddhartha, Hamilton, Betty, Hildebrandt, Gerhard C., Lekakis, Lazaros J., Liu, Hongtao, Maziarz, Richard T., Modi, Dipenkumar, Murthy, Hemant S., Preussler, Jaime M., Sharma, Akshay, Spellman, Stephen R., Arora, Mukta, and Lee, Stephanie J.
Published: 2022
Full Text: View/download PDF

35. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma

Author: Moustafa, Muhamad Alhaj, Ramdial, Jeremy L., Tsalatsanis, Athanasios, Khimani, Farhad, Dholaria, Bhagirathbhai, Bojanini, Leyla, Brooks, Taylor Rey, Zain, Jasmine, Bennani, N. Nora, Braunstein, Zachary, Brammer, Jonathan E., Beitinjaneh, Amer, Jagadeesh, Deepa, Weng, Wen Kai, Kumar, Ambuj, Kharfan-Dabaja, Mohamed A., Ahmed, Sairah, and Murthy, Hemant S.
Published: 2024
Full Text: View/download PDF

36. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Author: Merryman, Reid W., Castagna, Luca, Giordano, Laura, Ho, Vincent T., Corradini, Paolo, Guidetti, Anna, Casadei, Beatrice, Bond, David A., Jaglowski, Samantha, Spinner, Michael A., Arai, Sally, Lowsky, Robert, Shah, Gunjan L., Perales, Miguel-Angel, De Colella, Jean Marc Schiano, Blaise, Didier, Herrera, Alex F., Shouse, Geoffrey, Spilleboudt, Chloe, Ansell, Stephen M., Nieto, Yago, Badar, Talha, Hamadani, Mehdi, Feldman, Tatyana A., Dahncke, Lori, Singh, Anurag K., McGuirk, Joseph P., Nishihori, Taiga, Chavez, Julio, Serritella, Anthony V., Kline, Justin, Mohty, Mohamad, Dulery, Remy, Stamatoulas, Aspasia, Houot, Roch, Manson, Guillaume, Moles-Moreau, Marie-Pierre, Orvain, Corentin, Bouabdallah, Kamal, Modi, Dipenkumar, Ramchandren, Radhakrishnan, Lekakis, Lazaros, Beitinjaneh, Amer, Frigault, Matthew J., Chen, Yi-Bin, Lynch, Ryan C., Smith, Stephen D., Rao, Uttam, Byrne, Michael, Romancik, Jason T., Cohen, Jonathon B., Nathan, Sunita, Phillips, Tycel, Joyce, Robin M., Rahimian, Maryam, Bashey, Asad, Ballard, Hatcher J., Svoboda, Jakub, Torri, Valter, Sollini, Martina, De Philippis, Chiara, Magagnoli, Massimo, Santoro, Armando, Armand, Philippe, Zinzani, Pier Luigi, and Carlo-Stella, Carmelo
Published: 2021
Full Text: View/download PDF

37. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

Author: Percival, Mary-Elizabeth, Wang, Hai-Lin, Zhang, Mei-Jie, Saber, Wael, de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Abdel-Azim, Hisham, Adekola, Kehinde, Aljurf, Mahmoud, Bacher, Ulrike, Badawy, Sherif M., Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Castillo, Paul, Chao, Nelson, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Dias, Ajoy, Diaz, Miguel Angel, Estey, Elihu, Farhadfar, Nosha, Frangoul, Haydar A., Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hossain, Nasheed, Kamble, Rammurti T., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Krem, Maxwell, Lazarus, Hillard M., Lee, Jong Wook, Liesveld, Jane L., Lin, Richard, Liu, Hongtao, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Palmisiano, Neil, Passweg, Jakob R., Prestidge, Tim, Ringdén, Olov, Rizzieri, David A., Rybka, Witold B., Savoie, Mary Lynn, Schultz, Kirk R., Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, van der Poel, Marjolein, Verdonck, Leo F., Yared, Jean A., Weisdorf, Daniel, and Sandmaier, Brenda M.
Published: 2021
Full Text: View/download PDF

38. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Author: Farhadfar, Nosha, Dias, Ajoy, Wang, Tao, Fretham, Caitrin, Chhabra, Saurabh, Murthy, Hemant S., Broglie, Larisa, D'Souza, Anita, Gadalla, Shahinaz M., Gale, Robert Peter, Hashmi, Shahrukh, Al-Homsi, A. Samer, Hildebrandt, Gerhard C., Hematti, Peiman, Rizzieri, David, Chee, Lynette, Lazarus, Hillard M., Bredeson, Christopher, Jaimes, Edgar A., Beitinjaneh, Amer, Bashey, Asad, Prestidge, Tim, Krem, Maxwell M., Marks, David I., Benoit, Stefanie, Yared, Jean A., Nishihori, Taiga, Olsson, Richard F., Freytes, Cesar O., Stadtmauer, Edward, Savani, Bipin N., Sorror, Mohamed L., Ganguly, Siddhartha, Wingard, John R., and Pasquini, Marcelo
Published: 2021
Full Text: View/download PDF

39. Lower Incidence of Cytomegalovirus Reactivation Following Post-Transplantation Cyclophosphamide HLA-Mismatched Unrelated Donor Transplantation

Author: Camargo, Jose F, Ebisu, Yosuke, Jimenez-Jimenez, Antonio, Natori, Yoichiro, Moroz, Ilona, Morris, Michele I, Alencar, Maritza, Anderson, Anthony D, Lekakis, Lazaros, Beitinjaneh, Amer, Goodman, Mark, Wang, Trent, Pereira, Denise, and Komanduri, Krishna V.
Published: 2021
Full Text: View/download PDF

40. Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis

Author: Blue, Brandon J., Brazauskas, Ruta, Chen, Karen, Patel, Jinalben, Zeidan, Amer M., Steinberg, Amir, Ballen, Karen, Kwok, Janette, Rotz, Seth J., Perez, Miguel Angel Diaz, Kelkar, Amar H., Ganguly, Siddhartha, Wingard, John R., Lad, Deepesh, Sharma, Akshay, Badawy, Sherif M., Lazarus, Hillard M., Hashem, Hasan, Szwajcer, David, Knight, Jennifer M., Bhatt, Neel S., Page, Kristin, Beattie, Sara, Arai, Yasuyuki, Liu, Hongtao, Arnold, Staci D., Freytes, César O., Abid, Muhammad Bilal, Beitinjaneh, Amer, Farhadfar, Nosha, Wirk, Baldeep, Winestone, Lena E., Agrawal, Vaibhav, Preussler, Jaime M., Seo, Sachiko, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William A., Rangarajan, Hemalatha G., Saber, Wael, and Majhail, Navneet S.
Published: 2023
Full Text: View/download PDF

41. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS

Author: Gupta, Vikas, Kim, Soyoung, Hu, Zhen-Huan, Liu, Ying, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Gadalla, Shahinaz M., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gerds, Aaron T., Gergis, Usama, Hamilton, Betty K., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Kamble, Rammurti T., Kindwall-Keller, Tamila, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Maziarz, Richard T., Nishihori, Taiga, Olsson, Richard F., Rizzieri, David, Savani, Bipin N., Seo, Sachiko, Solh, Melhem, Szer, Jeff, Verdonck, Leo F., Wirk, Baldeep, Woolfrey, Ann, Yared, Jean A., Alyea, Edwin P., Popat, Uday R., Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael
Published: 2020
Full Text: View/download PDF

42. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities

Author: Gutierrez, Cristina, Brown, Anne Rain T., Herr, Megan M., Kadri, Sameer S., Hill, Brian, Rajendram, Prabalini, Duggal, Abhijit, Turtle, Cameron J., Patel, Kevin, Lin, Yi, May, Heather P., Gallo de Moraes, Alice, Maus, Marcela V., Frigault, Mathew J., Brudno, Jennifer N., Athale, Janhavi, Shah, Nirali N., Kochenderfer, James N., Dharshan, Ananda, Beitinjaneh, Amer, Arias, Alejandro S., McEvoy, Colleen, Mead, Elena, Stephens, R. Scott, Nates, Joseph L., Neelapu, Sattva S., and Pastores, Stephen M.
Published: 2020
Full Text: View/download PDF

43. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Author: Kahn, Justine M., Brazauskas, Ruta, Tecca, Heather R., Bo-Subait, Stephanie, Buchbinder, David, Battiwala, Minoo, Flowers, Mary E.D., Savani, Bipin N., Phelan, Rachel, Broglie, Larisa, Abraham, Allistair A., Keating, Amy K., Daly, Andrew, Wirk, Baldeep, George, Biju, Alter, Blanche P., Ustun, Celalettin, Freytes, Cesar O., Beitinjaneh, Amer M., Duncan, Christine, Copelan, Edward, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Auletta, Jeffery J., Myers, Kasiani C., Williams, Kirsten M., Page, Kristin M., Vrooman, Lynda M., Norkin, Maxim, Byrne, Michael, Diaz, Miguel Angel, Kamani, Naynesh, Bhatt, Neel S., Rezvani, Andrew, Farhadfar, Nosha, Mehta, Parinda A., Hematti, Peiman, Shaw, Peter J., Kamble, Rammurti T., Schears, Raquel, Olsson, Richard F., Hayashi, Robert J., Gale, Robert Peter, Mayo, Samantha J., Chhabra, Saurabh, Rotz, Seth J., Badawy, Sherif M., Ganguly, Siddhartha, Pavletic, Steven, Nishihori, Taiga, Prestidge, Tim, Agrawal, Vaibhav, Hogan, William J., Inamoto, Yoshihiro, Shaw, Bronwen E., and Satwani, Prakash
Published: 2020
Full Text: View/download PDF

44. Survival following allogeneic transplant in patients with myelofibrosis

Author: Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael
Published: 2020
Full Text: View/download PDF

45. Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Author: DeFilipp, Zachariah, Ancheta, Richard, Liu, Ying, Hu, Zhen-Huan, Gale, Robert Peter, Snyder, David, Schouten, Harry C., Kalaycio, Matt, Hildebrandt, Gerhard C., Ustun, Celalettin, Daly, Andrew, Ganguly, Siddhartha, Inamoto, Yoshihiro, Litzow, Mark, Szer, Jeffrey, Savoie, Mary Lynn, Hossain, Nasheed, Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Reshef, Ran, Bajel, Ashish, Schultz, Kirk R., Gadalla, Shahinaz, Gerds, Aaron, Liesveld, Jane, Juckett, Mark B., Kamble, Rammurti, Hashmi, Shahrukh, Abdel-Azim, Hisham, Solh, Melhem, Bacher, Ulrike, Lazarus, Hillard, Olsson, Richard, Cahn, Jean-Yves, Grunwald, Michael R., Savani, Bipin N., Yared, Jean, Rowe, Jacob M., Cerny, Jan, Chaudhri, Naeem A., Aljurf, Mahmoud, Beitinjaneh, Amer, Seo, Sachiko, Nishihori, Taiga, Hsu, Jack W., Ramanathan, Muthalagu, Alyea, Edwin, Popat, Uday, Sobecks, Ronald, and Saber, Wael
Published: 2020
Full Text: View/download PDF

46. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Author: Oran, Betül, Cortes, Jorge, Beitinjaneh, Amer, Chen, Hsiang-Chun, de Lima, Marcos, Patel, Keyur, Ravandi, Farhad, Wang, Xuemei, Brandt, Mark, Andersson, Borje, Ciurea, Stefan, Santos, Fabio, de Padua Silva, Leandro, Shpall, Elizabeth, Champlin, Richard, Kantarjian, Hagop, and Borthakur, Gautam
Subjects: AML, Allogeneic stem cell transplantation, FLT3-ITD mutation, Postremission therapy, Aged, Alleles, Consolidation Chemotherapy, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Nucleophosmin, Prognosis, Propensity Score, Recurrence, Remission Induction, Survival Analysis, Tandem Repeat Sequences, Transplantation, Homologous, Treatment Outcome, fms-Like Tyrosine Kinase 3
Abstract: The adverse prognosis of internal tandem duplication in the FMS-like tyrosine kinase 3 gene(s) (FLT3-ITD) in patients with acute myelogenous leukemia (AML) may depend on allelic burden. We compared postremission treatment with chemotherapy and hematopoietic stem cell transplantation (HSCT) in 169 FLT3-ITDmut intermediate cytogenetic risk AML patients with allelic ratio evaluable at diagnosis who achieved first complete remission (CR1) with induction therapy. To minimize selection bias, the analysis was limited to patients who remained in CR1 for at least 4 months (median time to HSCT) after achieving CR1, and propensity score matching was implemented. Sensitivity analysis including patients who remained in CR1 for at least 3 months was applied as well. HSCT in CR1 was associated with longer relapse-free survival (RFS) and overall survival (OS), with 3-year estimated rates of 18% and 24%, respectively (P
Published: 2016

47. Intensive Care Risk and Long-Term Outcomes in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Author: Zinter, Matt S, primary, Brazauskas, Ruta, additional, Strom, Joelle, additional, Chen, Stella, additional, Bo-Subait, Stephanie, additional, Sharma, Akshay, additional, Beitinjaneh, Amer, additional, Dimitrova, Dimana, additional, Guilcher, Gregory, additional, Preussler, Jaime M., additional, Myers, Kasiani C, additional, Bhatt, Neel S., additional, Ringden, Olle, additional, Hematti, Peiman, additional, Hayashi, Robert J., additional, Patel, Sagar S., additional, De Oliveira, Satiro, additional, Rotz, Seth J., additional, Badawy, Sherif M, additional, Nishihori, Taiga, additional, Buchbinder, David K, additional, Hamilton, Betty K., additional, Savani, Bipin N, additional, Schoemans, Hélène M., additional, Sorror, Mohamed Lotfy, additional, Winestone, Lena E., additional, Duncan, Christine, additional, Phelan, Rachel, additional, and Dvorak, Christopher C, additional
Published: 2023
Full Text: View/download PDF

48. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia

Author: Narayan, Rupa, Niroula, Abhishek, Wang, Tao, Kuxhausen, Michelle, He, Meilun, Meyer, Everett, Chen, Yi-Bin, Bhatt, Vijaya Raj, Beitinjaneh, Amer, Nishihori, Taiga, Sharma, Akshay, Brown, Valerie I., Kamoun, Malek, Diaz, Miguel A., Abid, Muhammad Bilal, Askar, Medhat, Kanakry, Christopher G., Gragert, Loren, Bolon, Yung-Tsi, Marsh, Steven G.E., Gadalla, Shahinaz M., Paczesny, Sophie, Spellman, Stephen, and Lee, Stephanie J.
Published: 2023
Full Text: View/download PDF

49. Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation

Author: Sabloff, Mitchell, Chhabra, Saurabh, Wang, Tao, Fretham, Caitrin, Kekre, Natasha, Abraham, Allistair, Adekola, Kehinde, Auletta, Jeffery J., Barker, Christopher, Beitinjaneh, Amer M., Bredeson, Christopher, Cahn, Jean-Yves, Diaz, Miguel Angel, Freytes, Cesar, Gale, Robert Peter, Ganguly, Siddhartha, Gergis, Usama, Guinan, Eva, Hamilton, Betty K., Hashmi, Shahrukh, Hematti, Peiman, Hildebrandt, Gerhard, Holmberg, Leona, Hong, Sanghee, Lazarus, Hillard M., Martino, Rodrigo, Muffly, Lori, Nishihori, Taiga, Perales, Miguel-Angel, Yared, Jean, Mineishi, Shin, Stadtmauer, Edward A., Pasquini, Marcelo C., and Loren, Alison W.
Published: 2019
Full Text: View/download PDF

50. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis

Author: Farhadfar, Nosha, Murthy, Hemant S., Logan, Brent R., Sees, Jennifer A., Ayas, Mouhab, Battiwalla, Minoo, Beitinjaneh, Amer M., Chhabra, Saurabh, Diaz, Miguel Angel, Engles, Katie, Frangoul, Haydar, Ganguly, Siddhartha, Gergis, Usama, Kamani, Nayesh R., Kamble, Rammurti T., Kasow, Kimberly A., Lazarus, Hillard M., Liesveld, Jane L., Norkin, Maxim, O’ Donnell, Paul V., Olsson, Richard F., Rossmann, Susan, Savani, Bipin N., Schears, Raquel, Seo, Sachiko, Solh, Melhem M., Spitzer, Thomas, Sugrue, Michele, Yared, Jean A., Linenberger, Michael, Schwartz, Joseph, Pulsipher, Michael A., Shah, Nirali N., Switzer, Galen E., Confer, Dennis L., Shaw, Bronwen E., and Wingard, John R.
Published: 2020
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

663 results on '"Beitinjaneh, Amer"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources